丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响

doi:10.3969/j.issn.1673-5765.2023.03.008

摘要/Abstract

摘要： 目的探讨心源性卒中患者使用丁苯酞对华法林抗凝作用的影响。
方法前瞻性连续纳入成都医学院第一附属医院神经内科2019年6月—2021年12月期间收治的心源性卒中患者，患者入组后随机分为试验组（华法林+丁苯酞）和对照组（华法林）。监测两组患者的国际标准化比值（international standardized ratio，INR）变化情况并收集两组患者的临床资料，比较分析两组患者的INR达标时间、2周内达标率和90 d mRS评分的差异。
结果本研究共纳入101例心源性卒中患者，试验组51例，对照组50例。两组基线数据（年龄、性别、用药前INR、收缩压和舒张压）差异无统计学意义，入院时试验组的NIHSS评分[10（3.0～15.0）分 vs. 0（0～6.5）分，P<0.001]，溶栓率（27.5% vs. 8.0%，P=0.011）与取栓率（25.5% vs. 2.0%，P=0.001）均高于对照组。试验组INR 2周内达标率与对照组相比差异无统计学意义（43.1% vs. 44.0%，P=0.930）。试验组达标时间较对照组明显缩短[（6.50±2.41）d vs.（9.64±4.40）d，P=0.015]。试验组90 d mRS评分与对照组相比，差异无统计学意义[3（0.5～4.0）分 vs. 2（0～3.0）分，P=0.175]。
结论丁苯酞联合华法林治疗心源性卒中可能缩短华法林的达标时间，需进一步的研究来验证，但对于INR的达标率和90 d mRS评分无影响。

文章导读： 丁苯酞联合华法林治疗心源性卒中能够缩短华法林的达标时间，若口服华法林抗凝的患者同时使用丁苯酞，则在启动抗凝后应该更早复查凝血指标。

关键词: 丁苯酞; 华法林; 心源性卒中

Abstract: Objective To investigate the effect of butylphthalide on warfarin anticoagulation in patients with cardiogenic stroke.
Methods The patients with cardiogenic stroke admitted to the Department of Neurology of the First Affiliated Hospital of Chengdu Medical College from June 2019 to December 2021 were consecutively enrolled in this prospective study. All the patients were randomly divided into observation group (warfarin+butylphthalide) and control group (warfarin). The changes of international standardized ratio (INR) and clinical data of the two groups were collected. The time of INR reaching the target, the rate of reaching the target within 2 weeks and the mRS score at 90 days were compared and analyzed between the two groups.
Results A total of 101 subjects were included in this study, with 51 cases in each group. There were no statistical differences in the baseline data of age, gender, INR before treatment, systolic and diastolic blood pressure between the two groups. The NIHSS score at admission [10 (3.0-15.0) vs. 0 (0-6.5), P<0.001], and the proportionof thrombolytic and thrombectomy patients (27.5% vs. 8.0%, P=0.011; 25.5% vs. 2.0%, P=0.001) were higher than that in the control group. There was no statistical difference in the rate of INR reaching the target within 2 weeks between the two groups (43.1% vs. 44.0%, P=0.930). The time to reach the target in the observation group was shorter than that in the control group [(6.50±2.41) d vs. (9.64±4.40) d, P=0.015]. There was no statistical difference in mRS score at 90 days between the two groups [3 (0.5-4.0) vs. 2 (0-3.0) , P=0.175].
Conclusions Butylphthalide combined with warfarin in treatment of cardiogenic stroke may shorten the time to reach the target of warfarin, which needs further study to verify, while it had no effect on the rate of INR reaching the target and 90-day mRS score.

Key words: Butylphthalide; Warfarin; Cardiogenic stroke

许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍. 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响[J]. 中国卒中杂志, 2023, 18(03): 288-294.

XU Tianzhu, PENG Shiyu, YANG Min, CHENG Hang, YIN Ying, LIU Yong, LIU Mingquan, YU Jianping.

Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke

[J]. Chinese Journal of Stroke, 2023, 18(03): 288-294.

参考文献

[1] 中华医学会老年医学分会老年神经病学组，心源性卒中诊断中国专家共识撰写组. 心源性卒中诊断中国专家共识（2020）[J]. 中华老年医学杂志，2020，39（12）：1369-1378.
[2] LIN S P，LONG Y，CHEN X H，et al. STAF score is a new simple approach for diagnosing cardioembolic stroke[J]. Int J Neurosci，2017，127（3）：261-266.
[3] MARNANE M，DUGGAN C A，SHEEHAN O C，et al. Stroke subtype classification to mechanism-specific and undetermined categories by TOAST，A-S-C-O，and causative classification system：direct comparison in the north Dublin population stroke study[J]. Stroke，2010，41（8）：1579-1586.
[4] MURTAGH B，SMALLING R W. Cardioembolic stroke[J]. Curr Atheroscler Rep，2006，8（4）：310-316.
[5] KHOO C W，LIP G Y. Clinical outcomes of acute stroke patients with atrial fibrillation[J]. Expert Rev Cardiovasc Ther，2009，7（4）：371-374.
[6] 中华医学会老年医学分会老年神经病学组，北京神经科学学会血管神经病学专业委员会，心源性卒中治疗中国专家共识组. 心源性卒中治疗中国专家共识（2022）[J]. 中华医学杂志，2022，102（11）：760-773.
[7] ANSELL J，HIRSH J，HYLEK E，et al. Pharmacology and management of the
vitamin k antagonists[J/OL]. Chest，2008，133（6）：160S-198S[2022-07-04]. https://doi.org/10.1378/chest. 08-0670.
[8] BARRIOS V，ESCOBAR C，CALDERÓN A，et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care[J]. Revista Espanola De Cardiologia，2014，67（2）：150-151.
[9] REIFFEL J A. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?[J]. Curr Opin Cardiol，2004，19（1）：58-63.
[10] CHEN X Q，QIU K，LIU H，et al. Application and prospects of butylphthalide for the treatment of neurologic diseases[J]. Chin Med J，2019，132（12）：1467-1477.
[11] TIAN Z Y，WANG J H，WANG Y，et al. Effects of butylphthalide on cognitive decline in diabetic rats[J]. Mol Med Rep，2017，16（6）：9131-9136.
[12] LUO R X，WANGQIN R Q，ZHU L H，et al. Neuroprotective mechanisms of 3-n-butylphthalide in neurodegenerative diseases[J]. Biomed Rep，2019，11（6）：235-240.
[13] WANG Y，BI Y，XIA Z L，et al. Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia[J]. Biochem Biophys Res Commun，2018，497（1）：80-86.
[14] YANG C S，GUO A，Li Y，et al. Dl-3-n-butylphthalide reduces neurovascular inflammation and ischemic brain injury in mice[J]. Aging and disease，2019，10（5）：964.
[15] 缺血性卒中脑侧支循环评估与干预中国指南（2017）[J]. 中华内科杂志，2017，56（6）：460-471.
[16] 中华医学会神经病学分会，中华医学会神经
病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志，2018，51（9）： 666-682.
[17] KERNAN W N，OVBIAGELE B，BLACK H R，et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke，2014，45（7）：2160-2236.
[18] MANCIA G，FAGARD R，NARKIEWICZ K，et al. 2013 Practice guidelines for the management of arterial hypertension of the European society of hypertension（ESH）and the European society of cardiology（ESC）：ESH/ESC task force for the management of arterial hypertension[J]. J Hypertens，2013，31（10）：1925-1938.
[19] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2013年版）[J]. 中华糖尿病杂志，2014，6（7）： 447-498.
[20] LOPES R D，ELLIOTT L E，WHITE H D，et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention：results from the APEX-AMI trial[J]. Eur Heart J，2009，30（16）：2019-2028.
[21] JANUARY C T，WANN L S，ALPERT J S，et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J/OL]. J Am Coll Cardiol，2014，64（21）：e1-e76[2022-07-04]. https://doi.org/10.1016/j.jacc.2014. 03.022.
[22] DE VECCHIS R，CANTATRIONE C，MAZZEI D. Clinical relevance of anticoagulation and dual antiplatelet therapy to the outcomes of patients with atrial fibrillation and recent percutaneous coronary intervention with stent[J]. J Clin Med Res，2016，8（2）：153-161.
[23] HANKEY G J，PATEL M R，STEVENS S R，et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack：a subgroup analysis of ROCKET AF[J]. Lancet Neurol，2012，11（4）：315-322.
[24] STERNE J A，BODALIA P N，BRYDEN P A，et al. Oral anticoagulants for primary prevention，treatment and secondary prevention of venous thromboembolic disease，and for prevention of stroke in atrial fibrillation：systematic review，network meta-analysis and cost-effectiveness analysis[J]. Health Technol Assess，2017，21（9）：1-386.
[25] WANG H L，YE K，LI D，et al. DL-3-n-butylphthalide for acute ischemic stroke：an updated systematic review and meta-analysis of randomized controlled trials[J/OL]. Front Pharmacol，2022，13：963118[2022-07-04]. https://doi. org/10.3389/fphar. 2022.963118.
[26] CHEN Y H，JIANG M J，LI L，et al. DL‑3‑n‑butylphthalide reduces microglial activation in lipopolysaccharide‑induced Parkinson's disease model mice[J]. Mol Med Rep，2018，17（3）：3884-3890.
[27] ZHU T，WANG L，FENG Y C，et al. Classical active ingredients and extracts of Chinese herbal medicines：pharmacokinetics，pharmacodynamics，and molecular mechanisms for ischemic stroke[J/OL]. Oxid Med Cell Longev，2021：8868941[2022-07-04]. https://doi.org/10.1155/2021/8868941.
[28] JIANG W X，YU X D，DENG Y. Effect of Butylphthalide combined with oxiracetam on cognitive function，intellectual recovery and serum inflammatory factors in patients with cognitive impairment after cerebral infarction[J]. Pak J Med Sci，2023，39（2）：485-490.
[29] WANG S，MA F，HUANG L J，et al. Dl-3-n-butylphthalide（NBP）：a promising therapeutic agent for ischemic stroke[J]. CNS Neurol Disord Drug Targets，2018，17（5）：338-347.